A Look At Ionis Pharmaceuticals (IONS) Valuation After Strong One Year Returns And Recent Pullback [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
Why Ionis Pharmaceuticals Is on Investors' Radar Ionis Pharmaceuticals (IONS) has been drawing attention after recent price moves, with shares last closing at US$73.27. Investors are weighing this level against the company's fundamentals, recent returns and pipeline-driven revenue profile. See our latest analysis for Ionis Pharmaceuticals. The recent pullback, with a 1-day share price return of a 1.11% decline at US$73.27, comes after a 1-year total shareholder return of 146.70%. This suggests some investors may be reassessing near term risks while the longer term story remains intact. If Ionis's biotech profile has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 33 healthcare AI stocks With Ionis posting a 1 year total return above 140%, double digit annual revenue growth and an analyst price target implying room above US$73.27, you have to ask: is there still upside here, or is the market already baking in future growth?
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis BBusiness Wire
- Ionis Pharmaceuticals (IONS) had its price target lowered by TD Cowen from $110.00 to $108.00. They now have a "buy" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) was upgraded by Canaccord Genuity Group Inc. to "strong-buy".MarketBeat
- Ionis (IONS) Q4 2025 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Ionis Pharmaceuticals (IONS) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
IONS
Earnings
- 2/25/26 - Miss
IONS
Sec Filings
- 4/28/26 - Form 144
- 4/23/26 - Form DEF
- 4/23/26 - Form ARS
- IONS's page on the SEC website